ClinicalTrials.gg
CompletedNCT07889271Updated Oct 22, 2026

Hand Grip Strength Correlates Strongly With Weekly Working Hours - the Importance of Upper Limb Function in Multiple Sclerosis

An observational study in Multiple Sclerosis, sponsored by Salzburger Landeskliniken. Completed at 1 site in Austria. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Salzburger Landeskliniken · Observational

Updated Oct 22, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
300
Sex
All
01

Study summary

Multiple sclerosis (MS) as leading cause of non-traumatic neurological disability in young adults has additionally to the individual's burden of disease a significant influence on their ability to work.

Objective of this study is to test parameters for their correlation with weekly working hours.

We will retrospectively analyse data of people with MS (pwMS) and correlate weekly working hours with demographics, Expanded Disability Status Scale (EDSS), Nine Hole Peg Test (9HPT), walking speed measured by Timed 25-Foot Walk test (T25FW), Symbol Digit Modalities Test (SDMT) and Hand Grip Strength (HGS).

02

Conditions studied

  • Multiple Sclerosis

Browse trials for

03

In context

Multiple Sclerosis

3,524 studies on the registry are indexed under Multiple Sclerosis; 668 are open to participants now.

This study's enrollment of 300 is above the median of 100 across 1,034 observational studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Salzburger Landeskliniken is the lead sponsor of 15 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

MS patients which include the 9HPT, T25FW, HGS and SDMT at least once during the study period as part of their routine examinations

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

This cross-sectional study analyse data from MS patients using the McDonald criteria of 2024 at the MS outpatient clinic in Salzburg, Austria between February 2024 until June 2026. Measurements included the 9HPT, T25FW, HGS and SDMT at least once during the study period as part of their routine examinations

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
300 participants (actual)
Patient registry
No

Interventions

  • Behavioralhand grip strength

    The HGS test is a measure of upper extremity muscle strength and muscle function (17). The test was performed in seated position with lower extremities on the ground and with the elbow angle of 90 degrees. Saehan dynamometer with string mechanism and scale displaying the measured value in kilograms (kg) was used. Participants were asked to press the dynamometer as strong as possible, three times with each hand, and the highest result in each hand was recorded and subsequently the average of both hands was calculated.

06

What researchers measure

Primary outcomes

  1. Correlation of routine parameters with weekly working hours

    Correlation of Expanded Disability Status Scale (EDSS), Nine Hole Peg Test (9HPT), walking speed measured by Timed 25-Foot Walk test (T25FW), Symbol Digit Modalities Test (SDMT) and Hand Grip Strength (HGS) with weekly working hours

    Time frame: From Feb 2024 to June 2026

07

Study locations

1 site
  • SalzburgerLandeskliniken
    Salzburg, State of Salzburg 5020, Austria
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Jun 2026, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2026
First posted
Oct 22, 2026
StartActual
Feb 1, 2024
Primary completionActual
Jun 1, 2026
CompletionActual
Jun 1, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07889271
Lead sponsor
Salzburger Landeskliniken
Responsible party
Peter Wipfler (apl. Prof., Salzburger Landeskliniken) — Principal investigator
First posted
Oct 22, 2026
Start date
Feb 1, 2024
Primary completion
Jun 1, 2026
Completion
Jun 1, 2026
Last update
Oct 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion